Edwards Lifesciences Q4 FY25: where the revenue came from and where it went
The whole income statement of Edwards Lifesciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Oct 1 – Dec 31, 2025
- Reported
- Feb 25, 2026
Revenue$1.57B
+13% year over year
Gross profit$1.23B
78% margin
Operating profit$0.15B
10% margin
Net profit$0.09B
6% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.57 | 100% | +13% |
| Aortic valve replacement | 1.16 | 74% | +12% |
| Surgical heart valve therapy | 0.25 | 16% | +4% |
| Transcatheter mitral | 0.16 | 10% | +48% |
| Cost of revenue | −0.34 | 22% | |
| Gross profit | 1.23 | 78% margin | −1pp |
| R&D | −0.27 | 17% | +0pp |
| SG&A | −0.60 | 39% | +0pp |
| Other | −0.21 | 13% | +0pp |
| Operating profit | 0.15 | 10% margin | +0pp |
| Interest & other costs | −0.03 | ||
| Tax | −0.03 | ||
| Net profit | 0.09 | 6% margin | −22pp |
154 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest